Business
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in event of exposure to cholera due to
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in event of exposure to cholera due to bioterrorism or advancement of cholera into US territories due to global warmingCholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeJaguar to present August 10th at Emerging Growth Conference; Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentationSAN FRANCISCO, CA / ACCESSWIRE / August 9, 2023 / Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it has submitted a Stage 1 funding application to the Biomedical Advanced Research and Development Authority (BARDA) for development of NP-300, the company's novel drug product candidate for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral and parasitic infections including Vibrio cholerae, the bacterium that causes cholera. BARDA, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).\"We are seeking funding from BARDA to help fund the Phase 1, Phase 2, and Phase 3 studies for development of NP-300 with an eye toward increasing American preparedness and response time in the event of exposure to cholera due to bioterrorism or the advancement of cholera into U.S. territories due to global warming,\" said Steve King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer. \"If BARDA expresses interest in this initiative, the next step would be for Napo to proceed to Stage 2 of the application process, which would involve submitting a full proposal to BARDA.\"As announced, Napo's Investigational New Drug (IND) application for NP-300 was activated by the U.S. Food and Drug Administration (FDA) in September 2022. In support of the IND application filing, the company received partial financial support for certain IND-enabling preclinical toxicity studies from the National Insti...